Tags

Type your tag names separated by a space and hit enter

Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.
Rheumatology (Oxford). 2013 Oct; 52(10):1914-9.R

Abstract

OBJECTIVE

The primary objective of this retrospective study was to investigate the possibility of achieving partial remission (PR) in AS patients treated with anti-TNF-α antagonists, such as adalimumab (ADA), etanercept (ETA) and infliximab (INF), in a real clinical practice setting. Predictors of PR were also evaluated.

METHODS

A retrospective study was conducted in patients with AS treated with ADA, ETA and INF from 2000 to 2012. Kaplan-Meier survival curves were plotted to determine the rates of PR during the treatment with anti-TNF-α drugs.

RESULTS

A total of 283 patients with AS were treated with ADA (18.7%), ETA (26.8%) and INF (54.4%) as first anti-TNF-α drugs, with a PR rate of 57.6%. The probability of obtaining PR with ADA, ETA or INF was not significantly different among all anti-TNF-α patients. AS patients treated with a second anti-TNF-α drug had a PR rate of 40.5%, but after switching for lack of response, the probability of obtaining PR with a second anti-TNF-α drug was significantly lower from that of the first anti-TNF-α drug (P = 0.0039). The probability of obtaining PR in patients with enthesitis (P = 0.04) or psoriasis (P = 0.0016) or low levels of CRP (P = 0.0225) was significantly lower compared with that of patients without these manifestations at baseline.

CONCLUSION

Our real-life study on PR confirmed the effectiveness of ADA, ETA or INF as first or second anti-TNF-α drugs. The presence at baseline of enthesitis or psoriasis or low CRP values yielded a lower probability of obtaining PR.

Authors+Show Affiliations

Dipartimento di Medicina Interna e Specialità Mediche - UOC di Reumatologia - Sapienza - Università di Roma, Azienda Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy. a.spadaro.reuma@virgilio.it.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

23878312

Citation

Spadaro, Antonio, et al. "Remission in Ankylosing Spondylitis Treated With anti-TNF-α Drugs: a National Multicentre Study." Rheumatology (Oxford, England), vol. 52, no. 10, 2013, pp. 1914-9.
Spadaro A, Lubrano E, Marchesoni A, et al. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford). 2013;52(10):1914-9.
Spadaro, A., Lubrano, E., Marchesoni, A., D'Angelo, S., Ramonda, R., Addimanda, O., Perrotta, F. M., Olivieri, I., Punzi, L., & Salvarani, C. (2013). Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford, England), 52(10), 1914-9. https://doi.org/10.1093/rheumatology/ket249
Spadaro A, et al. Remission in Ankylosing Spondylitis Treated With anti-TNF-α Drugs: a National Multicentre Study. Rheumatology (Oxford). 2013;52(10):1914-9. PubMed PMID: 23878312.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. AU - Spadaro,Antonio, AU - Lubrano,Ennio, AU - Marchesoni,Antonio, AU - D'Angelo,Salvatore, AU - Ramonda,Roberta, AU - Addimanda,Olga, AU - Perrotta,Fabio Massimo, AU - Olivieri,Ignazio, AU - Punzi,Leonardo, AU - Salvarani,Carlo, Y1 - 2013/07/22/ PY - 2013/7/24/entrez PY - 2013/7/24/pubmed PY - 2013/11/14/medline KW - ankylosing spondylitis KW - anti-TNF-α drugs KW - remission SP - 1914 EP - 9 JF - Rheumatology (Oxford, England) JO - Rheumatology (Oxford) VL - 52 IS - 10 N2 - OBJECTIVE: The primary objective of this retrospective study was to investigate the possibility of achieving partial remission (PR) in AS patients treated with anti-TNF-α antagonists, such as adalimumab (ADA), etanercept (ETA) and infliximab (INF), in a real clinical practice setting. Predictors of PR were also evaluated. METHODS: A retrospective study was conducted in patients with AS treated with ADA, ETA and INF from 2000 to 2012. Kaplan-Meier survival curves were plotted to determine the rates of PR during the treatment with anti-TNF-α drugs. RESULTS: A total of 283 patients with AS were treated with ADA (18.7%), ETA (26.8%) and INF (54.4%) as first anti-TNF-α drugs, with a PR rate of 57.6%. The probability of obtaining PR with ADA, ETA or INF was not significantly different among all anti-TNF-α patients. AS patients treated with a second anti-TNF-α drug had a PR rate of 40.5%, but after switching for lack of response, the probability of obtaining PR with a second anti-TNF-α drug was significantly lower from that of the first anti-TNF-α drug (P = 0.0039). The probability of obtaining PR in patients with enthesitis (P = 0.04) or psoriasis (P = 0.0016) or low levels of CRP (P = 0.0225) was significantly lower compared with that of patients without these manifestations at baseline. CONCLUSION: Our real-life study on PR confirmed the effectiveness of ADA, ETA or INF as first or second anti-TNF-α drugs. The presence at baseline of enthesitis or psoriasis or low CRP values yielded a lower probability of obtaining PR. SN - 1462-0332 UR - https://www.unboundmedicine.com/medline/citation/23878312/Remission_in_ankylosing_spondylitis_treated_with_anti_TNF_α_drugs:_a_national_multicentre_study_ L2 - https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/ket249 DB - PRIME DP - Unbound Medicine ER -